share_log

The Flowr Corporation Announces First Quarter 2022 Results and Reinstatement of Trading

The Flowr Corporation Announces First Quarter 2022 Results and Reinstatement of Trading

Flowr公司宣佈2022年第一季度業績和恢復交易
GlobeNewswire ·  2022/05/30 20:01

Highlights:

重點:

  • In Q1 2022, the Company generated gross revenue of $3.9 million as a result of the sale of 1,179,735 grams of dried cannabis flower, an increase of 75% compared to Q1, 2021
  • Net loss decreased by $2.2 million in Q1, 2022 or 26% to a loss of $6.1 million compared to Q1, 2021
  • SG&A expenses in Q1 2022 were $2.9 million, or 29% lower than Q1, 2021
  • 2022年第一季度,該公司銷售了1,179,735克幹大麻花,毛收入為390萬美元,較2021年第一季度增長75%
  • 與2021年第一季度相比,2022年第一季度淨虧損減少220萬美元,降幅26%,至虧損610萬美元
  • 2022年第一季度的SG&A費用為290萬美元,比2021年第一季度下降29%

Key Subsequent Events:

後續關鍵事件:

  • During Q2, the Company paid $1.6 million from the Holigen sale towards the repayment of the ATB Term Facility upon closing of the transaction.
  • 在第二季度,該公司從Holigen出售中支付了160萬美元,用於在交易完成時償還ATB定期貸款。

TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) ("Flowr" or the "Company") herein announces its financial and operational results for the first quarter results for the period ended March 31, 2022.   All financial information in this news release is reported in thousands ('$000s) of Canadian dollars and represents results from continuing operations, unless otherwise indicated.

多倫多,2022年5月30日(環球社)--The Flowr Corporation(多倫多證券交易所股票代碼:FLWR;場外交易代碼:FLWPF)(““或”公司“)在此宣佈其截至2022年3月31日的第一季度的財務和運營業績。本新聞稿中的所有財務信息都以數千加元(‘000美元)報告,除非另有説明,否則代表持續運營的結果。

Tom Flow, Interim Chief Executive Officer of Flowr, commented:

Flowr臨時首席執行官Tom Flow評論道:

"The first quarter of 2022 showed that we remain on track with our objective on maintaining our status as a premium cannabis producer. Also, our continued focus on cost reductions is showing in our bottom-line improvements."

2022年第一季度表明,我們仍在實現保持優質大麻生產商地位的目標。此外,我們繼續專注於降低成本,這體現在我們的底線改善上。

SELECTED FINANCIAL AND OPERATIONAL RESULTS

精選財務和運營結果

The following table summarizes the Company's key financial and operational results:

下表彙總了該公司的主要財務和經營業績:

In thousands of CAD dollars,   Three months ended
 
(except loss per share and grams harvested)   March 31,
 
    2022     2021  
Grams harvested - K1   1,232,654     669,307  
Grams sold   1,179,735     672,566  
Gross revenue   3,878     4,403  
Net revenue   3,463     3,622  
Cost of sales   3,678     2,730  
Impairment of inventory   683     749  
Gross profit/(loss) before fair value adjustments   (898 )   143  
Selling and marketing and G&A   2,852     3,999  
Share-based compensation   (225 )   421  
Impairment of assets   29      
Loss/(gain) from disposal of subsidiary       (54 )
Net loss   (5,762 )   (7,081 )
Basic and diluted loss per share   (0.01 )   (0.02 )
以數千加元計, 截至三個月
(每股虧損和收穫的克數除外) 3月31日,
2022 2021
收穫的克數-K1 1,232,654 669,307
售出的克數 1,179,735 672,566
毛收入 3,878 4,403
淨收入 3,463 3,622
銷售成本 3,678 2,730
存貨減值 683 749
公允價值調整前毛利/(虧損) (898 ) 143
銷售、市場營銷和併購 2,852 3,999
基於股份的薪酬 (225 ) 421
資產減值 29
出售子公司的虧損/(收益) (54 )
淨虧損 (5,762 ) (7,081 )
每股基本虧損和攤薄虧損 (0.01 ) (0.02 )

Financial Results (presented in $000s)

財務業績(以2000美元為單位)

  • Gross revenue for Q1 2022 was $3,878 compared to $4,403 in Q1 2021, a decline of $525 or 12%. Net revenue during Q1 2022 was $3,463, $159 or 4% lower than Q1 2021. The decrease in revenue is primarily a result of a lower average net sale price, partially offset by higher volume. Sale of retail products during Q1 2022 was 257 kilograms compared with 541 kilograms in Q1 2021. Sale of cannabis through bulk wholesale channels during Q1 2022 was 923 kilograms compared to 131 kilograms in Q1 2021 primarily due to higher production from the K1 facility.
  • SG&A expenses for Q1 2022 was $2,852 compared with $3,999 in Q1 2021, a decrease of $1,147 or 29% primarily as a result cost reduction measures the Company implemented that began 2021 and continued in 2022.
  • Gross loss for Q1 2022 was $898 compared with a profit of $143 for Q1 2021 primarily as a result a lower profit margin on products sold.
  • Cost of sales for Q1 2022 was $3,678 compared to $2,730 for Q1 2021. The increase in cost of sales resulted from a significantly higher volume of cannabis sold during the current quarter at 1,180 kilograms compared with 673 kilograms sold during Q1 2021.
  • The Company recorded impairment charges totaling $29 in Q1 2022 compared with $nil in Q1 2021.
  • Net loss of the Company totaled $5,762 for Q1 2022 compared to a loss of $7,081 for Q1 2021. The change in net loss was primarily due to a higher gross loss more than offset by lower SG&A, a reversal in share-based compensation, lower depreciation and finance costs.
  • 與2021年第一季度的4,403美元相比,2022年第一季度的毛收入為3,878美元,下降了525美元或12%。2022年第一季度的淨收入為3,463美元,比2021年第一季度下降159美元或4%。收入的減少主要是由於平均淨銷售價格下降,但部分被較高的銷量所抵消。2022年第一季度零售產品銷售額為257公斤,而2021年第一季度為541公斤。2022年第一季度通過大宗批發渠道銷售的大麻為923公斤,而2021年第一季度為131公斤,這主要是由於K1工廠的產量增加。
  • 與2021年第一季度的3,999美元相比,2022年第一季度的SG&A費用為2,852美元,減少了1,147美元或29%,這主要是由於公司從2021年開始實施並於2022年繼續實施的成本削減措施。
  • 2022年第一季度的總虧損為898美元,而2021年第一季度的利潤為143美元,這主要是由於銷售產品的利潤率較低。
  • 2022年第一季度的銷售成本為3678美元,而2021年第一季度的銷售成本為2730美元。銷售成本的增加是因為本季度的大麻銷售量大幅增加,為1180公斤,而2021年第一季度的銷售量為673公斤。
  • 本公司於2022年第一季度記錄的減值費用總額為29美元,而2021年第一季度的減值費用為零。
  • 2022年第一季度,公司淨虧損總額為5,762美元,而2021年第一季度虧損為7,081美元。淨虧損的變化主要是由於較高的總虧損被較低的SG&A、以股份為基礎的薪酬逆轉、較低的折舊和融資成本所抵消。

Operational Updates

運營更新

  • Q1 2022, Flowr continued full operation in all 20 grow rooms at the K1 facility and improved the THC level by an average of +4.9% in comparison to Q1 2021. 
  • Q1 2022 harvest yield was 84% higher than Q1 2021 (1,232,654 grams vs 669, 307 grams).  
  • Flowr has further increased its product offerings in Q1 2022 with the launch of BC Vanilla Frost and BC Tropical Zktlz in Quebec, BC Clementine Crush into British Columbia, and BC Strawnana in Alberta. 
  • In Q1 2022 Flowr continued to trial more than 50 new genetic strains to offer consumers differentiated exotic genetics, with high THC, high terpene contents, strong sensory profiles and premium quality buds.  
  • The Company has made significant steps to improve product quality in Q1 2022, by adding a processing step to sort buds post-harvest, as well as adding moisture control packs to bulk and retail products. 
  • The Company has shown significant growth in retail penetration across its core markets of Ontario, Alberta and British Columbia with more than 60% of stores carrying a Flowr product. 
  • 2022年第一季度,Flowr繼續在K1設施的所有20個種植室全面運營,與2021年第一季度相比,THC水平平均提高了+4.9%。
  • 2022年第一季度的收穫產量比2021年第一季度(1,232,654克對669,307克)高出84%。
  • Flowr在2022年第一季度進一步增加了產品供應,在魁北克推出了BC Vanilla Frost和BC Tropical Zktlz,在不列顛哥倫比亞省推出了BC Clementine Crush,在艾伯塔省推出了BC Strawnana。
  • 2022年第一季度,Flowr繼續試驗50多個新的遺傳菌株,為消費者提供差異化的外來遺傳學,具有高THC、高萜類含量、強烈的感官特徵和優質的芽。
  • 該公司在2022年第一季度採取了重大措施來提高產品質量,增加了採摘後分揀花蕾的處理步驟,並在散裝和零售產品中增加了水分控制包裝。
  • 該公司在安大略省、艾伯塔省和不列顛哥倫比亞省等核心市場的零售滲透率出現了顯著增長,超過60%的商店銷售Flowr產品。

Adjusted EBITDA (Non-IFRS Measure)

調整後的EBITDA(非國際財務報告準則計量)

Adjusted EBITDA is defined as net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense) including finance costs, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus restructuring and transaction costs, plus (minus) loss (gain) on investments, plus impairment charges, and plus (minus) unusual or non-recurring items. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.

調整後的EBITDA定義為淨虧損加上(減去)所得税(回收),加上(減去)包括財務成本的利息收入(支出),加上折舊和攤銷,加上基於股票的薪酬,加上(減去)出售的生物資產和存貨的非現金公允價值調整,加上重組和交易成本,加上(減去)投資損失(收益),加上減值費用,加上(減去)異常或非經常性項目。管理層認為,這一衡量標準提供了有用的信息,因為它是資本市場常用的衡量標準,也是業務活動使用的可重複現金的密切代表。

For a full discussion of Flowr's operational and financial results for the year ended December 31, 2021, please refer to the Company's Management's Discussion & Analysis and Consolidated Financial Statements for the year ended December 31, 2021, which have been filed on SEDAR.

有關Flowr截至2021年12月31日的年度的經營和財務業績的全面討論,請參閲已在SEDAR上提交的公司管理層截至2021年12月31日的年度的討論與分析和綜合財務報表。

Reinstatement of Trading

恢復營業

The Company is pleased to announce that the failure-to-file cease trade order issued by the Ontario Securities Commission on May 6, 2022 ("FFCTO") against the Company has been fully revoked by the applicable regulatory authorities.

本公司欣然宣佈,安大略省證券事務監察委員會於2022年5月6日發出的未能提交停止交易令(“FFCTO“)已被適用的監管當局完全撤銷。

The FFCTO was issued as a result of the Company's failure to file the following periodic disclosure documents (the "Annual Filings") by the filing deadline of May 2, 2022:

FFCTO的發佈是由於公司未能提交以下定期披露文件(“年度提交文件“)在2022年5月2日的提交截止日期前:

  • the audited annual financial statements of the Company for the year ended December 31, 2021;
  • the management's discussion and analysis of the Company for the year ended December 31, 2021; and
  • certificates of each of the Interim Chief Executive Officer and the Chief Financial Officer relating to the audited annual financial statements.
  • 本公司截至2021年12月31日的經審計年度財務報表;
  • 管理層對本公司截至2021年12月31日止年度的討論及分析;及
  • 臨時首席執行官和首席財務官關於經審計的年度財務報表的證書。

The Annual Filings were filed on SEDAR on May 20, 2022.

年報於2022年5月20日在SEDAR上提交。

As previously announced on May 11, 2022, effective May 6, 2022, the TSX Venture Exchange ("TSXV") suspended trading in the Company's securities as a result of the issuance of the FFCTO. The Company applied to the TSXV for the reinstatement of trading of the Company's securities on the TSXV. The reinstatement of trading of the Company's securities on the TSXV was granted by the TSXV on May 27, 2022 and the common shares of Flowr will be reinstated to trade effective at the opening on May 31, 2022.

正如此前於2022年5月11日宣佈的那樣,自2022年5月6日起,多倫多證券交易所創業板(TSX)TSXV“)因FFCTO發行而暫停本公司證券的交易。本公司向多倫多證券交易所申請恢復本公司證券在多倫多證券交易所的交易。於2022年5月27日,多倫多證券交易所批准恢復本公司證券在多倫多證券交易所的交易,Flowr的普通股將於2022年5月31日開盤時恢復交易。

In addition, further to the Company's press release dated May 2, 2022 in respect of the completion of the sale of Holigen Holdings (the "Holigen Sale"), an arm's length third party received a cash payment of C$1,250,478.72 and 96,354 common shares of Akanda Corp. as an advisory fee in connection with the services provided to the Company in relation to the Holigen Sale.

此外,繼本公司於2022年5月2日就完成出售Holigen Holdings(“Holigen大甩賣“),一名公平第三方收到1,250,478.72加元和96,354股Akanda Corp.普通股的現金付款,作為與向本公司提供與Holigen出售有關的服務有關的諮詢費。

About The Flowr Corporation

關於Flowr公司

The Flowr Corporation is a Canadian cannabis company with its operating campus located in Kelowna, British Columbia. Flowr aims to support improving outcomes through responsible cannabis use and, as an established expert in cannabis cultivation, strives to be the brand of choice for consumers and patients seeking the highest-quality craftsmanship and product consistency across a portfolio of differentiated cannabis products.  

The Flowr Corporation是一家加拿大大麻公司,其運營園區位於不列顛哥倫比亞省基洛納。Flowr的目標是通過負責任的大麻使用來支持改善結果,作為大麻種植方面的知名專家,Flowr努力成為消費者和患者的首選品牌,他們希望通過一系列差異化的大麻產品組合獲得最高質量的工藝和產品一致性。

For more information, please visit flowrcorp.com or follow Flowr on Twitter: @FlowrCanada and LinkedIn: The Flowr Corporation.

欲瞭解更多信息,請訪問Flowrcorp.com或在推特上關注Flowr:@FlowrCanada和LinkedIn:The Flowr Corporation。

On behalf of The Flowr Corporation:

我代表Flowr公司:

Tom Flow
Interim Chief Executive Officer

TOM流
臨時行政總裁

CONTACT INFORMATION:

聯繫方式:

INVESTORS & MEDIA:
investors@flowrcorp.com

投資者和媒體:
郵箱:Investors@flow rcorp.com

Forward-Looking Information:

前瞻性信息:

Certain statements made in this press release may constitute "forward-looking information", "future oriented financial information" or "financial outlooks" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information may relate to anticipated events or results including, but not limited to: the Company's expectation that it will build on its achievements as it continues to invest in sales and marketing; the Company's expectations for sales of product in Quebec; Flowr's business, production and products; Flowr's plans to provide premium quality cannabis to adult use recreational and medical markets; EU-GMP certification opening the medicinal cannabis opportunity for the Company in global markets; the Company being well positioned to distribute EU-GMP compliant product into underserviced markets; the Company's ability to obtain licensing from Health Canada and other regulatory authorities with respect to its properties and facilities; future legislative and regulatory developments in Canada and elsewhere; the cannabis industry in Canada generally; the ability of Flowr to implement its business strategies; and the ability of Flowr to produce or sell premium quality cannabis. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "believe", "estimate", "plan", "could", "should", "would", "outlook", "forecast", "anticipate", "foresee", "continue" or the negative of these terms or variations of them or similar terminology. Forward-looking information is current as of the date it is made and is based on reasonable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. To the extent any forward-looking information in this press release constitutes "future oriented financial information" or "financial outlooks", within the meaning of applicable securities laws, the purpose of such information being provided is to demonstrate the potential of the Company and readers are cautioned that this information may not be appropriate for any other purpose. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking information as discussed in the Company's other publicly filed documents, which can be accessed under the Company's profile on the System for Electronic Document Analysis and Retrieval ("SEDAR") at . The Company cautions that the list of risk factors and uncertainties described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

本新聞稿中的某些陳述可能構成“前瞻性信息”、“面向未來的財務信息”或“財務展望”(統稱為“前瞻性信息“)在適用的證券法的含義內。前瞻性信息可能與預期的事件或結果有關,這些事件或結果包括但不限於:公司在繼續投資於銷售和營銷的同時將在其成就的基礎上再接再厲的期望;公司對魁北克產品銷售的期望;Flowr的業務、生產和產品;Flowr向成人娛樂和醫療市場提供優質大麻的計劃;EU-GMP認證為公司在全球市場打開醫用大麻的機會;公司能夠很好地向服務不足的市場銷售符合EU-GMP的產品;該公司獲得加拿大衞生部和其他監管機構對其物業和設施的許可的能力;加拿大和其他地方未來的立法和監管發展;加拿大大麻行業的總體情況;Flowr實施其商業戰略的能力;以及Flowr生產或銷售優質大麻的能力。具體地説,有關我們對未來結果、目標、業績成就、前景或機會的預期的信息是前瞻性信息。前瞻性陳述常常但並非總是可以通過使用前瞻性術語來識別,如“可能”、“將”、“預期”、“相信”、“估計”、“計劃”、“可能”、“應該”、“將”、“展望”、“預測”、“預期”、“預見”、“繼續”或這些術語的否定或它們的變體或類似術語。前瞻性信息是截至發佈之日的最新信息,基於我們在相關時間根據我們對歷史趨勢、當前狀況和預期未來發展的經驗和看法做出的合理估計和假設。, 以及我們認為在這種情況下適當和合理的其他因素。如果本新聞稿中的任何前瞻性信息構成適用證券法所指的“面向未來的財務信息”或“財務展望”,則提供此類信息的目的是展示公司的潛力,請讀者注意,此類信息可能不適用於任何其他目的。然而,我們不承諾因新信息、未來事件或其他原因而更新任何此類前瞻性信息,除非加拿大適用的證券法要求。不能保證這樣的估計和假設將被證明是正確的。許多因素可能會導致我們的實際結果、活動水平、業績或成就或未來的事件或發展與公司其他公開申報文件中討論的前瞻性信息所表達或暗示的內容存在實質性差異。這些前瞻性信息可根據公司在電子文件分析和檢索系統上的簡介(“SEDAR“)。公司提醒,AIF中描述的風險因素和不確定因素並非詳盡無遺,其他因素也可能對其結果產生不利影響。請讀者在評估前瞻性信息時仔細考慮風險、不確定因素和假設,並告誡不要過度依賴這些信息。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論